Marc Miravitlles

Author PubWeight™ 6.41^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.	Int J Chron Obstruct Pulmon Dis	2015	0.91
2	Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.	Drug Discov Today	2014	0.90
3	Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.	PLoS One	2014	0.87
4	Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.	Int J Chron Obstruct Pulmon Dis	2016	0.76
5	POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe.	Int J Chron Obstruct Pulmon Dis	2016	0.76
6	Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.	Int J Chron Obstruct Pulmon Dis	2017	0.75
7	Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.	Adv Ther	2016	0.75
8	Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.	Int J Chron Obstruct Pulmon Dis	2015	0.75
9	Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.	J Am Med Dir Assoc	2017	0.75
10	GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort.	Eur Respir J	2017	0.75
11	Erratum to: Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.	Adv Ther	2017	0.75
12	Impact and prevention of severe exacerbations of COPD: a review of the evidence.	Int J Chron Obstruct Pulmon Dis	2017	0.75